Review of Interventional Therapies for Refractory Pediatric Migraine
This is a review of the latest and seminal evidence in pediatric migraine. It covers the etiology and pathophysiology known today, and then will review treatment options, efficacy and safety, quality of data and indications. Though migraine is usually regarded as an infliction in adults, it is not uncommon in the pediatric population and affects up to 8% of children. Children may experience migraine differently than adults, and present not only with headache but also frequent gastrointestinal symptoms. They are frequently shorter in duration than in adults. Traditional migraine treatment in adults is less effective in children. In this population, adjunct therapies – such as interventional techniques – should be considered when traditional treatment fails, including Botulinum Toxin A (BTA) injections, peripheral nerve and ganglion blocks. BTA injections are FDA approved for migraine prophylaxis in adults, but currently not in children; however, recent evidence shows efficacy and safety in pediatric migraine management. Nerve blocks stop nociceptive afferent fibers through injection of local anesthetics, and it may be associated with the local injection of corticosteroids. Although more common in adults, recent data suggests they are safe and effective in children and adolescents. Blocking the sphenopalatine ganglion can be achieved through nasal approach, and achieves a similar action by blocking the entire ganglion. Interventional techniques may provide a key component in the alleviation of this otherwise debilitating chronic migraine pain. Though most studies have been performed in adults, new studies provide encouraging results for treatment in children.
1. Faber AJ, Lagman-Bartolome AM, Rajapakse T. Drugs for the acute treatment of migraine in children and adolescents. Paediatr Child Health. 2017;22(8):454-458. doi:10.1093/pch/pxx170
2. Papetti L, Ursitti F, Moavero R, et al. Prophylactic treatment of pediatric migraine: Is there anything new in the last decade? Front Neurol. 2019;10(JUL). doi:10.3389/fneur.2019.00771
3. Oskoui M, Pringsheim T, Billinghurst L, et al. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2019;93(11):500-509. doi:10.1212/wn1.0000000000008105
4. Gelfand AA, Goadsby PJ. Medication overuse in children and adolescents. Curr Pain Headache Rep. 2014;18(7). doi:10.1007/s11916-014-0428-1
5. Durham PL, Cady R. Insights into the mechanism of onabotulinumtoxinA in chronic migraine. Headache. 2011;51(10):1573-1577. doi:10.1111/j.1526-4610.2011.02022.x
6. Herd CP, Tomlinson CL, Rick C, et al. Botulinum toxins for the prevention of migraine in adults. Cochrane Database of Systematic Reviews. 2018;2018(6). doi:10.1002/14651858.cd011616.pub2
7. Chan VW, Mccabe EJ, Macgregor DL. Botox treatment for migraine and chronic daily headache in adolescents. J Neurosci Nurs. 2009;41(5):235-243. doi:10.1097/jnn.0b013e3181aaa98f
8. Young WB, Ivan Lopez J, Rothrock JF, et al. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: Results from the COMPEL Study. J Headache Pain. 2019;20(1):12. doi:10.1186/s10194-018-0953-0
9. Ahmed K, Oas KH, Mack KJ, Garza I. Experience with botulinum toxin type A in medically intractable pediatric chronic daily headache. Pediatr Neurol. 2010;43(5):316-319. doi:10.1016/j.pediatmeurol.2010.06.001
10. Kabbouche M, O’Brien H, Hershey AD. OnabotulinumtoxinA in pediatric chronic daily headache. Curr Neurol Neurosci Rep. 2012;12(2):114-117. doi:10.1007/s11910-012-0251-1
11. Allergan. BOTOX Cosmetic (onabotulinumtoxinA) for injection, for intramuscular use. U.S. Food and Drug Administration; 2015.
12. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. doi:10.1177/0333102417738202
13. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804-814. doi:10.1177/0333102410364677
14. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793-803. doi:10.1177/0333102410364676
15. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine | Guidance | NICE.
16. Ali SS, Bragin I, Rende E, Mejico L, Werner KE. Further Evidence that Onabotulinum Toxin is a Viable Treatment Option for Pediatric Chronic Migraine Patients. Cureus. 2019;11(3). doi:10.7759/cureus.4343
17. Shah S, Calderon MD, Wu WD, Grant J, Rinehart J. Onabotulinumtoxin A (BOTOX®) for Prophylactic Treatment of Pediatric Migraine: A Retrospective Longitudinal Analysis. J Child Neurol. 2018;33(9):580-586. doi:10.1177/0883073818776142
18. Szperka CL, Gelfand AA, Hershey AD. Patterns of Use of Peripheral Nerve Blocks and Trigger Point Injections for Pediatric Headache: Results of a Survey of the American Headache Society Pediatric and Adolescent Section. Headache. 2016;56(10):1597-1607. doi:10.1111/head.12939
19. Mulero P, Guerrero AL, Pedraza M, et al. Non-traumatic supraorbital neuralgia: A clinical study of 13 cases. Cephalalgia. 2012;32(15):1150-1153. doi:10.1177/0333102412459575
20. Speciali JG, Godoi Goncalves DA. Auriculotemporal neuralgia. Current Pain and Headache Reports. 2005;9(4):277-280. doi:10.1007/s11916-005-0037-0
21. Blumenfeld A, Ashkenazi A, Napchan U, et al. Expert consensus recommendations for the performance of peripheral nerve blocks for headaches - A narrative review. Headache. 2013;53(3):437-446. doi:10.1111/head.12053
22. Ambrosini A, Vandenheede M, Rossi P, et al. Suboccipital injection with a mixture of rapid- and long-acting steroids in cluster headache: A double-blind placebo-controlled study. Pain. 2005;118(1-2):92-96. doi:10.1016/j.pain.2005.07.015
23. Ashkenazi A, Matro R, Shaw JW, Abbas MA, Silberstein SD. Greater occipital nerve block using local anaesthetics alone or with triamcinolone for transformed migraine: A randomised comparative study. J Neurol Neurosurg Psychiatry. 2008;79(4):415-417. doi:10.1136/jnnp.2007.124420
24. Ashkenazi A, Young WB. The effects of greater occipital nerve block and trigger point injection on brush allodynia and pain in migraine. Headache. 2005;45(4):350-354. doi:10.1111/j.1526-4610.2005.05073.x
25. Shields KG, Levy MJ, Goadsby PJ. Alopecia and cutaneous atrophy after greater occipital nerve infiltration with corticosteroid. Neurology. 2004;63(11):2193-2194. doi:10.1212/01.wnl.0000145832.26051.3c
26. Bartsch T. Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input. Brain. 2002;125(7):1496-1509. doi:10.1093/brain/awf166
27. Sprenger T, Seifert CL. Coma after greater occipital nerve blockade in a patient with previous posterior fossa surgery. Headache. 2013;53(3):548-550. doi:10.1111/head.12015
28. Okuda Y, Matsumoto T, Shinohara M, Kitajima T, Kim P. Sudden unconsciousness during a lesser occipital nerve block in a patient with the occipital bone defect. Eur J Anaesthesiol. 2001;18(12):829-832. doi:10.1097/00003643-200112000-00008
29. Ashkenazi A, Blumenfeld A, Napchan U, et al. Peripheral nerve blocks and trigger point injections in headache management - A systematic review and suggestions for future research. Headache. 2010;50(6):943-952. doi:10.1111/j.1526-4610.2010.01675.x
30. Karadas O, Ozon AO, Ozcelik F, Ozge A. Greater occipital nerve block in the treatment of triptan-overuse headache: A randomized comparative study. Acta Neurol Scand. 2017;135(4):426-433. doi:10.1111/ane.12692
31. Juskys R, Sustickas G. Effectiveness of treatment of occipital neuralgia using the nerve block technique: a prospective analysis of 44 patients. Acta medica Litu. 2018;25(2):53-60. doi:10.6001/actamedica.v25i2.3757
32. Zaremski JL, Hurley RW, Herman D, Bauer RM, Ahn AH. Poster 182 Occipital Neuralgia Blockade as a Treatment after Concussions. A Case Series. PM&R. 2014;6(9):S249. doi:10.1016/j.pmrj.2014.08.576
33. Seeger TA, Orr S, Bodell L, Lockyer L, Rajapakse T, Barlow KM. Occipital Nerve Blocks for Pediatric Posttraumatic Headache. J Child Neurol. 2015;30(9):1142-1146. doi:10.1177/0883073814553973
34. Dubrovsky AS, Friedman D, Kocilowicz H. Pediatric post-traumatic headaches and peripheral nerve blocks of the scalp: A case series and patient satisfaction survey. Headache. 2014;54(5):878-887. doi:10.1111/head.12334
35. Gelfand AA, Reider AC, Goadsby PJ. Outcomes of greater occipital nerve injections in pediatric patients with chronic primary headache disorders. Pediatr Neurol. 2014;50(2):135-139. doi:10.1016/j.pediatrneurol.2013.09.008
36. Puledda F, Goadsby PJ, Prabhakar P. Treatment of disabling headache with greater occipital nerve injections in a large population of childhood and adolescent patients: a service evaluation. J Headache Pain. 2018;19(1). doi:10.1186/s10194-018-0835-5
37. Lacey D. Efficacy of greater occipital nerve blocks (ONBs) in the treatment of chronic daily headaches (CDH) in adolescent females with fibromyalgia. Headache. Published online 2014.
38. Renaudon-Smith E, Goadsby P, Prabhakar P. Greater occipital nerve injection (GONI) for chronic headache in children. Headache Pain. 2010;11(Suppl 1):76.
39. Mumber H, Szperka C. Retrospective study of nerve blocks for the treatment of headaches in children and adolescents. Headache. 2016;56:37.
40. Binfalah M, Alghawi E, Shosha E, Alhilly A, Bakhiet M. Sphenopalatine Ganglion Block for the Treatment of Acute Migraine Headache. Pain Res Treat. 2018;2018:1-6. doi:10.1155/2018/2516953
41. Mehta D, Leary MC, Yacoub HA, et al. The Effect of Regional Anesthetic Sphenopalatine Ganglion Block on Self-Reported Pain in Patients With Status Migrainosus. Headache. 2019;59(1):69-76. doi:10.1111/head.13390
42. Lawrence L. Sphenopalatine Ganglion Block: Pediatric Migraine | Neurology Times.
43. Dance L, Aria D, Schaefer C, Kaye R, Yonker M, Towbin R. Safety and efficacy of sphenopalatine ganglion blockade in children: initial experience. J Vasc Interv Radiol. 2017;28(2):S8. doi:10.1016/j.jvir.2016.12.595
44. SPG Block for Acute Pediatric Migraine - Full Text View - ClinicalTrials.gov.